The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.
Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
Neffy (epinephrine nasal spray) 1mg is approved for the emergency treatment of type 1 allergic reactions, including ...
Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...
Vasomotor rhinitis is a cause of runny nose and congestion not related to allergies or an infection. Learn about the symptoms ...
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
In a move to expand its portfolio beyond antibiotics, Paratek Pharmaceuticals has bought out Optinose and its chronic ...
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic ...
OptiNose (NASDAQ:OPTN) stock surges 61% as Paratek Pharmaceuticals agrees to a $330M acquisition. Read mroe here.
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback